GB1420879A - Pseudodi- and trisaccharides and methods for their preparation - Google Patents

Pseudodi- and trisaccharides and methods for their preparation

Info

Publication number
GB1420879A
GB1420879A GB4643173A GB4643173A GB1420879A GB 1420879 A GB1420879 A GB 1420879A GB 4643173 A GB4643173 A GB 4643173A GB 4643173 A GB4643173 A GB 4643173A GB 1420879 A GB1420879 A GB 1420879A
Authority
GB
United Kingdom
Prior art keywords
group
hydroxy
protective
amino
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB4643173A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scherico Ltd
Original Assignee
Scherico Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scherico Ltd filed Critical Scherico Ltd
Publication of GB1420879A publication Critical patent/GB1420879A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/22Cyclohexane rings, substituted by nitrogen atoms
    • C07H15/222Cyclohexane rings substituted by at least two nitrogen atoms
    • C07H15/226Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings
    • C07H15/234Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to non-adjacent ring carbon atoms of the cyclohexane rings, e.g. kanamycins, tobramycin, nebramycin, gentamicin A2
    • C07H15/236Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to non-adjacent ring carbon atoms of the cyclohexane rings, e.g. kanamycins, tobramycin, nebramycin, gentamicin A2 a saccharide radical being substituted by an alkylamino radical in position 3 and by two substituents different from hydrogen in position 4, e.g. gentamicin complex, sisomicin, verdamycin
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

1420879 Pseudo di- and tri-saccharides, gentamicin derivatives and the preparation thereof SCHERICO Ltd 4 Oct 1973 [10 Oct 1972 20 Nov 1972 27 Aug 1973] 46431/73 Heading C2C Pseudotrisaccharides of the formula wherein R 1 represents hydroxy, R 2 represents hydrogen or hydroxy, R 3 represents hydroxy, amino or C 1-4 alkylamino, R 4 represents hydrogen or C 1-4 alkyl and R 5 represents hydroxy, amino or C 1-4 alkylamino, with the provisos (a) that when R 2 is hydroxy, R 4 is hydrogen or methyl and R 3 is amino, then R 5 is monosubstituted C 1-4 alkylamino, and (b) that when R 2 and R 3 are hydroxy, and R 4 is hydrogen or methyl, then R 5 is hydroxy or monosubstituted C 1-4 alkylamino, and pharmaceutically acceptable acid addition salts and Schiffs base oxazolidine derivatives thereof, may be obtained by condensing a selectively blocked garamine of the formula wherein each R 12 represents an amino protective group, and each R 11 represents hydrogen or a hydroxy protective group, and wherein R 12 in position 3<SP>1</SP> together with R 11 in position 4<SP>1</SP> may represent a protective group, and/or R 12 in positions 1 and 3 may together represent a protective group, e.g. a urea grouping, with a monosaccharide of the formula wherein hal represents halogen, R 14 represents -OR 13 and R 15 represents hydrogen or -OR 13 , X represents -OR 13 , -NRR 12 or an azido group, and Y represents -OR 13 , -NRR 12 or a nitroso group, R represents hydrogen or C 1-4 alkyl, and R 13 represents a hydroxy protective group, and when necessary subjecting the pseudotrisaccharide formed to one or two of the following steps in any appropriate order; (a) converting an oximino group in position 2<SP>1</SP> into group -NHR and/or an azido group in position 6<SP>1</SP> into -NH 2 ; (b) converting an oximino group in position 2<SP>1</SP> into hydroxy; or (c) converting a group -OR 13 in position 6<SP>1</SP> into a group -NHR; and subjecting the pseudotrisaccharide obtained from condensation or from one or two of steps (a) to (c) to an elimination of all protective groups present in the molecule, and, if desired, preparing a suitable salt or Schiffs base oxazolidine derivative. Gentamicin C 2a , a compound of Formula (I) wherein R 1 and R 2 are hydrogen, R 3 and R 5 are amino and R 4 is methyl, and which differs from gentamicin C 2 only in respect of the configuration at the 6<SP>1</SP>-carbon, is also claimed to be novel. The condensation of a compound of Formula (II) with a compound of Formula (III) may be effected in the presence of a catalyst such as mercuric cyanide or bromide, or silver carbonate, oxide, perchlorate or tosylate, optionally in the presence of a solvent. Conversion of the oximino group into the group -NHR may be effected by protection of the oximino group and subsequent reduction thereof, and where R is alkyl, the amino group formed upon reduction may be acylated with C 1-4 alkanoyl and the amide, so obtained, reduced. When the oximino group is acetylated and one or more hydroxy protective groups are acetyl, reduction may be effected with diborane. The amide group may also be formed by migration of an alkanoyl-hydroxy protective group to the amino group. Alternatively the oximino group may be converted into a keto group which is subsequently converted into a hydroxy group; the conversion of the oximino group into the keto group may be effected by means of levulinic acid, nitrous acid, titanium trichloride or thallium (III) nitrate, and conversion of the keto group into the hydroxy group may be effected by means of an alkali metal borohydride. Conversion of an azido group into an amino group may be effected by hydrogenation and the reaction may be carried out after conversion of the oximino group into the group -NHR. In step (c) above, conversion of the group -OR 13 into the group -NHR may be effected with RNH 2 or RNHNH 2 , or by transformation of the group -OR 13 into an azido group and subsequent reduction thereof. The elimination of all protective groups may be carried out by known methods such as hydrolysis, preferably in an alkaline medium, hydrogenolysis, or by means of hydrazine. Alkaline hydrolysis is preferably effected in reaction mixtures containing sodium hydroxide, sodium in ammonia, or ammonium hydroxide in methanol. The protected pseudotrisaccharide may be partially de-protected, e.g. with ammonium hydroxide, and subsequently fully de-protected in a stronger alkaline medium, e.g. sodium hydroxide. When the amino protective groups, together with the nitrogen atom to which they are attached in the 2-deoxy-D- streptamine ring, form carbamates and the deblocking is effected with a strong base, both amino groups in positions 1 and 3 may be protected with a bridging carbonyl group, i.e. to form a cyclic urea grouping, which may be removed in a very strong alkaline medium and preferably with hydrazine. Suitable protective groups may be selected from substituted or unsubstituted groups chosen from aryl, aralkyl, acyl, alkoxycarbonyl and aralkoxycarbonyl; specified amino protective groups include carbobenzoxy, t-butoxyearbonyl, 2,4-dinitrophenyl, 2,2,2-trichloroethoxycarbonyl, ethoxycarbonyl, methoxycarbonyl, acetyl, benzoyl, 2-iodo-ethoxycarbonyl, and p - methoxycarbobenzoxy; specified hydroxy protective groups include benzyl, p-nitrobenzyl and acetyl; or R 12 in position 3<SP>11</SP> together with R 11 in position 4<SP>11</SP> or both R 12 in positions 1 and 3 together may represent a carbonyl group. The monosaccharide starting materials of Formula III, wherein Y represents the nitroso group, may be prepared, for example, by reacting a nitrosyl halide with the corresponding monosaccharide having a 1,2- double bond. The pseudodisaccharides (also claimed to be novel) of the formula wherein R 10 is hydrogen or an amino protective group, R 11 is hydrogen or a hydroxy protective group and R 10 in position 3<SP>1</SP> and R 11 in position 4<SP>1</SP> together may represent a protective group, and/or R 10 in positions 1 and 3 together may represent a protective group, e.g. a urea grouping, may be obtained by selectively cleaving a compound of the formula and, when necessary, removing one or more protective groups and/or introducing one or more protective groups. The cleavage reaction may be effected by hydrolysis, under oxidative conditions, or by means of irradiation. The compounds of Formula (II) may be prepared by introducing the respective blocking group or groups into a compound of formula wherein R 14 is hydrogen or a hydroxy protective group more readily eliminatable than the other protective groups present in the molecule and wherein at least one of R 10 , R 11 and R 14 is hydrogen, followed, if desired, by elimination of the hydroxy protective group represented by R 14 . The pseudotrisaccharides exhibit antimicrobial, antiprotozoal, anthelmintic and antiviral activity and they may be formulated and applied in a known manner
GB4643173A 1972-10-10 1973-10-04 Pseudodi- and trisaccharides and methods for their preparation Expired GB1420879A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29643472A 1972-10-10 1972-10-10
US30806172A 1972-11-20 1972-11-20
US39191473A 1973-08-27 1973-08-27

Publications (1)

Publication Number Publication Date
GB1420879A true GB1420879A (en) 1976-01-14

Family

ID=27404431

Family Applications (1)

Application Number Title Priority Date Filing Date
GB4643173A Expired GB1420879A (en) 1972-10-10 1973-10-04 Pseudodi- and trisaccharides and methods for their preparation

Country Status (8)

Country Link
JP (1) JPS49100052A (en)
BG (1) BG21607A3 (en)
DE (1) DE2349974A1 (en)
ES (1) ES419364A1 (en)
FR (1) FR2201872B1 (en)
GB (1) GB1420879A (en)
IL (1) IL43368A0 (en)
NL (1) NL7313668A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0000473B1 (en) * 1977-06-24 1981-03-11 Scherico Ltd. Process for preparing aminoglycoside derivatives, novel derivatives obtained and pharmaceutical compositions containing such derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH79A (en) * 1889-01-09 Adam Sautter Johann Movement for pocket watches with an open barrel, new gear pusher system and simplified movement fastening
CH551965A (en) * 1970-06-22 1974-07-31 Scherico Ltd PROCESS FOR PRODUCING ANTIBIOTICALLY ACTIVE COMPOUNDS.
BE787758A (en) * 1971-11-08 1973-02-19 Scherico Ltd PROCESS FOR THE PREPARATION OF A SUBSTANCE WITH ANTIBIOTIC ACTIVITY CONTAINING A NEW ANTIBIOTIC, AND OF DERIVATIVES THEREOF

Also Published As

Publication number Publication date
DE2349974A1 (en) 1974-04-18
ES419364A1 (en) 1976-07-16
FR2201872A1 (en) 1974-05-03
IL43368A0 (en) 1974-01-14
BG21607A3 (en) 1976-07-20
JPS49100052A (en) 1974-09-20
AU6107173A (en) 1975-04-10
NL7313668A (en) 1974-04-16
FR2201872B1 (en) 1977-01-28

Similar Documents

Publication Publication Date Title
McKay et al. Preparation and properties of N-methyl-N-nitroso-N'-nitroguanidine
IE43937L (en) 1, 2, 4-triazole compounds.
SE8304239L (en) NEW INTERMEDIATES USED FOR THE PREPARATION OF OXIME DERIVATIVES OF 3-ACETOXIMETHYL-7-AMINOTIAZOLYL-ACET-AMIDOCEPHALOSPORANIC ACID AND PROCEDURES FOR PREPARING THE INTERMEDIATES
DE2012888B2 (en) Process for the preparation of 5-azapyrimidine nucleosides
GB1446082A (en) Kanamycin b derivatives active against drug-resistant bacteria and the production thereof
GB1383409A (en) Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them
DE2437160B2 (en) 1-N-ethylsisomicin and salts, processes for their preparation and pharmaceutical preparations containing these compounds
Tamura et al. N-amination of tertiary amines: a novel method for 1, 1, 1-trisubstituted hydrazinium salts
IE40052L (en) Piperidinoalkylindoles
GB1420879A (en) Pseudodi- and trisaccharides and methods for their preparation
HU218423B (en) N-acetil neuraminic acid derivates and method for producing thereof
IE32509B1 (en) Naphthacene derivatives
GB1456674A (en) Neomycin derivatives
IE42626L (en) 6-arylpyrroloimidazoles
GB1463282A (en) Sugar ureide and thiooureide derivatives
IE37422B1 (en) Benzofuran derivatives and a process for the manufacture thereof
ATE15375T1 (en) ANTHRACYCLINE GLYCOSIDES, INTERMEDIATE PRODUCTS, PROCESSES FOR BOTH MANUFACTURE AND PHARMACEUTICALS.
Goodman et al. Retention and racemization reactions during peptide synthesis
GB1425578A (en) Piperidine derivatives
SU1200852A3 (en) Method of producing tylosin derivatives
GB1108538A (en) New oxazolidine derivatives and process for their manufacture
GB1235778A (en) Amine derivatives
US3388164A (en) Method of preparing 1-adamantanamine
IE35379B1 (en) Erythromycylamine compounds
KR930023328A (en) N-methyldeacetylcol hisinamide derivative

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
PCNP Patent ceased through non-payment of renewal fee